Document:

EX-10.16

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
  

Exhibit 10.16 

AMENDMENT NO. 3 TO ANEMIA LICENSE AND
COLLABORATION AGREEMENT 
 This Amendment No. 3 (the “Amendment”) to the Anemia
License and Collaboration Agreement dated as of April 28, 2006, by and between Astellas Pharma Inc. (“Astellas”) and FibroGen, Inc. (“FibroGen”), as amended on August 31, 2006 and December 10, 2006
(the “Agreement”) is dated as of May 10, 2012 (the “Third Amendment Effective Date”). All capitalized terms not otherwise defined in this Amendment have the same meanings as set forth in the Agreement. 

WHEREAS, the Parties have entered into the Agreement, which provides that all costs and expenses
(including, without limitation, reasonable FTE costs and the Fully Burdened Cost of clinical supplies of the Product) incurred by either party for the Transatlantic Clinical Development Plan after the Effective Date shall be reported, adjusted and
reconciled between them on a quarterly basis so that FibroGen and Astellas are to share such costs and expenses equally; 

WHEREAS, the Parties intend to conduct multiple Phase 3 studies within the Transatlantic Clinical
Development Plan under the Agreement, including two (2) or more Phase 3 renal anemia studies in patients not on dialysis or in patients on dialysis treatment; and 

WHEREAS, the Parties would like to amend the cost sharing arrangement under the Agreement with respect to
certain activities performed in the conduct of the Phase 3 renal anemia studies to be conducted under the Agreement under a “payment in kind” schema, such that each Party shall bear solely the cost of such activities for the study for
which it is the Sponsor (as defined below), and such costs shall not be subject to the cost sharing provisions of the Agreement; 

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which
is hereby acknowledged, the Parties agree as follows: 
  

	(1)	Notwithstanding the provisions of the Agreement entitled “Development Costs” that outlines certain development costs that are to be shared by the Parties, solely with respect to the studies listed on
Exhibit A hereto (any such study sponsored by Astellas, an “Astellas Study”; and any such study sponsored by FibroGen, a “FibroGen Study”; each such Study, a “PIK Study”; and the Party sponsoring
such study, respectively, the “Sponsor”) all Development costs and expenses incurred for an Astellas Study or FibroGen Study, as the case may be, on and after the Third Amendment Effective Date, including, without limitation, those
incurred in connection with the following activities performed in the conduct of the study, including internal employee costs or out-of-pocket costs, whether incurred directly by the Sponsor or on the Sponsor’s behalf by any third party
(including, for the avoidance of doubt, the Party that is not the Sponsor of the Study upon express request of the Sponsor Party), shall be borne solely by the Sponsor (the “PIK Activities”): 

 — [ * ] 

 

	(2)	For the avoidance of doubt, notwithstanding Paragraph (1) above, all Development costs and expenses incurred in connection with the following activities performed in the conduct of the study, including internal
employee costs or out-of-pocket costs, whether incurred directly by the Sponsor or on the Sponsor’s behalf by any third party, shall be subject to the cost-sharing provisions of the Agreement: 

— [ * ] 

 

	(3)	The Parties agree and acknowledge that notwithstanding anything to the contrary in this Amendment, the conduct of all activities discussed in this Amendment shall remain subject to compliance with the terms and
conditions of the Agreement, and remain subject to JSC approval as set forth in the Agreement, irrespective of whether the costs relate to PIK Activities, except that JSC approval is not required with respect to the budget for the Development costs
and expenses set forth in Paragraph (1) above. 

  

	(4)	Except as otherwise provided herein, the Agreement has not been modified or amended and remains in full force and effect. All capitalized terms not defined herein shall have the meaning as set forth in the Agreement.

 IN WITNESS WHEREOF, the Parties have executed this Amendment No. 3 to Anemia License and Collaboration Agreement as of
the Third Amendment Effective Date. 
  

					
	FIBROGEN, INC.	 	
		
	By:  	 	             /s/ Thomas B.
Neff

		 	Thomas B. Neff, CEO

 
					
	
	ASTELLAS PHARMA INC.
		
	By:  	 	             /s/ C.
Yokota

		 	Chihiro Yokota, R.Ph.
		 	Corporate Executive
		 	Vice President, Licensing & Alliances

  
 2 

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been
omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 EXHIBIT A: ONGOING OR PLANNED PIK
STUDIES 
  

							
	 	  	 Sponsor
	  	 Study Code
	  	 Study description

	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
				
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
				
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]
				
	 [ * ]
	  	[ * ]	  	[ * ]	  	[ * ]

  
 3 

 [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and
filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.EX-10.19

 Exhibit 10.19 

[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the
Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 
 LICENSE AGREEMENT 

This Agreement, made and entered into this 23rd day of May, 1997 (the Effective Date”), by and between the UNIVERSITY OF MIAMI and its SCHOOL OF
MEDICINE, having its principal office at 1600 N.W. 10th Avenue, Miami, Florida 33136 (hereinafter “LICENSOR”) and FIBROGEN, INC., a corporation duly organized under the laws of Delaware
and having its principal office at 260 Littlefield Avenue, South San Francisco, California 94080 and its Affiliates (hereinafter collectively, “FIBROGEN”). 

WITNESSETH: 
 WHEREAS, LICENSOR is the
sole owner of the Technology and Product identified under the Patent Rights (as hereinafter defined) relating to Connective Tissue Growth Factor, and has the right to grant licenses under said Patent Rights; 

WHEREAS, LICENSOR desires to have the Patent Rights utilized in the public interest and is willing to grant an exclusive sublicense thereunder; 

WHEREAS, FIBROGEN intends to develop, produce, manufacture, market and/or sell products similar to the Licensed Product(s) (as hereinafter defined) and is
willing to commit itself to a diligent program of exploiting the Patent Rights so that public utilization shall result-therefrom; and 
 WHEREAS, FIBROGEN
desires to obtain a sublicense under the Patent Rights upon the terms and conditions hereinafter get forth. 
 NOW, THEREFORE, in consideration of the
premises and the mutual covenants contained herein, the parties agree as follows: 
 ARTICLE 1 

Definitions 
 1.1
“Affiliate” shall mean any corporation, company or other entity which directly or indirectly controls, or is controlled by, or is under common control with, FIBROGEN. For this purpose, “control” shall mean direct or
indirect beneficial ownership of at least fifty percent (50%) of the voting stock of, or at least a fifty percent (50%) interest in the income of such corporation or other business entity, or such other relationship as in fact, constitutes
actual control. 

 1.2 “FIBROGEN” shall mean FIBROGEN and shall include any Subsidiary (as
hereinafter defined) or Affiliate (as hereinafter defined) of FIBROGEN. 
 1.3 “Subsidiary” shall mean any corporation,
company or other entity at least fifty percent of whose voting stock is owned or controlled directly or indirectly by FIBROGEN. 
 1.4
“Patent Rights” shall mean United States Patent Application Serial Number [ * ] (hereinafter referred to as the “Patent Rights Patent Application”), and the United States and foreign patents issuing from
said United States and foreign patent applications or later-filed foreign applications based on the said United States Patents and applications (hereinafter referred to as the “Patent Rights Patent(s)”) and any continuations,
continuations-in-part, divisions, reissues or extensions of any of the foregoing. 
 1.5 “Licensed Method(s)” shall mean
the methods of treatment comprising the application and/or administration of connective tissue growth factor and related molecules which are covered in whole or in part by (i) a pending claim contained in a Patent Rights Patent Application, or
(ii) a valid and unexpired claim contained in a Patent Rights Patent. 
 1.6 “Licensed Process(s)” shall mean a
process for making Licensed Product(s) which is covered in whole or in part by (i) a pending claim contained in a Patent Rights Patent Application, or (ii) a valid and unexpired claim contained in a Patent Rights Patent. 

1.7 “Licensed Product(s)” shall mean any product used or sold and any process used by or for FIBROGEN, which at the time of
manufacture, use or sale: 
 (a) is covered in whole or in part by (i) a pending claim contained in a Patent Rights Patent Application
in the country in which the Licensed Product(s) is made, used or sold, or (ii) a valid and unexpired claim contained in a Patent Rights Patent in the country in which the Licensed Product(s) is made, used or sold; or 

(b) is manufactured by using a process that is a Licensed Process in the country in which such product is made, used or sold. 

1.8 “Net Sales” shall mean the sum of all amounts invoiced on account of sales or use of Products by FIBROGEN and any
sublicensees to non-Affiliated third-party purchasers or users of Products, less the sum of the following: 
 (a) discounts allowed in
amounts customary in the trade; 
 (b) sales, use, value-added, tariff duties or other excise taxes directly imposed and with reference to
particular sales; 
 (c ) outbound transportation prepaid or allowed; and 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 (d) amounts allowed or credited on returns. 

“Net Sales” shall not include any sale between or among FIBROGEN and its Affiliates or Subsidiaries, but shall include any subsequent sales by
FIBROGEN or its Affiliates or Subsidiaries. 
 No deductions shall be made for commissions paid to individuals, whether they be with
independent sales agencies or regularly employed by FIBROGEN and on its payroll, or for cost of collections. Licensed Product(s) shall be considered sold when used, billed out or invoiced. If the Licensed Product is exchanged for a consideration
other than money, billings shall be gross selling price of comparable Licensed Product(s) and in arm’s-length transactions by FIBROGEN or, if no sales of comparable Licensed Products have been made, then the fair market value thereof. 

1.9 “Net Royalties” shall mean the net royalties actually received by FIBROGEN in connection with sublicensing of any of the
Patent Rights. 
 1.10 “Effective Date” shall mean the date first shown above. 

1.11 “Territory” shall mean all the countries of the world. 

ARTICLE 2 
 Grant Of License

 2.1 LICENSOR hereby grants to FIBROGEN an exclusive worldwide right and license, with the right to sublicense others, to make, have
make, use, sell and have sold Licensed Product(a), and to practice Licensed Process(es) and/or Licensed Method(s), to the full end of the term for which the Patent Rights are granted (the “Contract Period”) unless sooner terminated
according to the terms hereof. 
 2.2 FIBROGEN agrees to forward to LICENSOR a copy of any and all fully executed sublicense agreements, and
further agrees to forward to LICENSOR annually a copy of such reports received by FIBROGEN from its sulicensees during the preceding twelve-month period under the sublicenses as shall be pertinent to a royalty accounting under said sublicense
agreements. 
 2.3 LICENSOR reserves to itself the right to practice under the Patent Rights for the University’s noncommercial
research and education purposes. 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 2.4 The license granted hereunder shall not be construed to confer any rights upon FIBROGEN by
implication, estoppel or otherwise as to any technology except as specifically set forth herein. 
 2.5 FIBROGEN agrees that any sublicenses
granted by it shall contain such provisions as are necessary for it to meet its obligations under this Agreement and to reasonably protect the interests of LICENSOR with regard to such sublicense. 

2.6 Termination under any of the provisions of this Agreement of the license granted to FIBROGEN in this Agreement shall terminate all
sublicenses which may have been granted by FIBROGEN, provided that any sublicensee may elect to continue its sublicense by advising LICENSOR in writing, within sixty days of the sublicensee’s receipt of written notice of such termination, of
its election and of its agreement to assume in respect to LICENSOR all the obligations (including obligations for payment) contained in its sublicensing agreement with FIBROGEN. Any sublicense granted by FIBROGEN shall contain provisions
corresponding to those of this paragraph respecting termination and the conditions of continuance of sublicenses. 
 ARTICLE III 

Due Diligence 
 3.1
FIBROGEN shall use best faith efforts to bring one or more Licensed Product(s), Licensed Method(s) and/or Licensed Process(es) to market through a diligent program for exploitation of the Patent Rights. 

3.2 FIBROGEN’s failure to perform in accordance with paragraph 3.1 above shall be grounds for LICENSOR to terminate this Agreement
pursuant to Paragraph 13.3 hereof. 
 3.3. FIBROGEN agrees to submit under confidence annual reports, upon LICENSOR’s request, as to
its efforts to develop markets for the Licensed Products and Licensed Method(s). Such reports shall include assurance by FIBROGEN of its intent to actively develop commercial embodiments of the inventions of the Licensed Patents and a summary of its
efforts in this regard. 
 3.4 Unless FIBROGEN has a Licensed Product available for commercial sale prior to January 1, 2008 or
FIBROGEN has made available for commercial sale a product which, when administered, may be used in a Licensed Method, FIBROGEN agrees that LICENSOR may terminate this Agreement 

ARTICLE 4 
 Royalties 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 4.1 For the rights, privileges and license granted hereunder, FIBROGEN shall pay fees and
royalties to LICENSOR, in the manner hereinafter provided, to the end of the term of the Patent Rights or until this Agreement shall be terminated as hereinafter provided: 

(a) FIBROGEN License Fee of [ * ] Dollars ($[ * ]) which said Fee shall be deemed earned and due immediately
upon the execution of this Agreement; 
 (b) Running Royalties equal to [ * ] Of Net Sales of the Licensed Products and/or
the sale of product which is labeled for a Licensed Method use; except that on Net Sales by or for sublicensees, FIBROGEN shall pay the lesser of [ * ] Of Net Sales or [ * ] of all royalties received by FIBROGEN
from any sublicense for Net Sales of the Licensed Products by or for the sublicensee; and 
 (c ) [ * ] of all License Fees
received by FIBROGEN from any sublicensee. As used in the preceding sentence, the term “License Fees” means any fees received by FIBROGEN for license of rights to the Licensed Products, Licensed Methods, Patent Rights, and Licensed
Processes, excluding (a) royalties and payments which are advances of future royalties and (b) payments for which FIBROGEN must render technical development services. 

4.2 In the case of sales in a country of a Licensed Product or Licensed Method based on a claim of a Patent Rights Patent Application that has
not issued as a Patent Rights Patent after [ * ] ([ * ]) years from the date of filing, the above-stated royalty rate shall be reduced by [ * ] ([ * ]) on Net Sales of such Licensed
Product and/or the sale of product which is labeled for a Licensed Method use in such country until such claim issues as a Patent Rights Patent or is rejected with no right of appeal or to which rejection neither party chooses to appeal. 

4.3 In the event that FIBROGEN manufactures, uses or sells a product which is related to connective tissue growth factor, including
derivatives of connective tissue growth factor, wherein the product is labeled for a Licensed Method use, FIBROGEN’s royalty payments under this Article 4 may be reduced in proportion to contributions to the development of the product by
FIBROGEN, to be determined through best faith negotiations of the parties. 
 4.4 If it is necessary to acquire one or more royalty bearing
licenses from third parties in order to fully exercise the rights granted by LICENSOR hereunder, then FIBROGEN shall be entitled to a credit against the royalty payments due hereunder, which credit shall be equal to the amount of the royalties
actually paid to such third parties, provided, in no case will the royalty otherwise due LICENSOR be reduced by more than fifty percent (50%) for such credit. 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 4.5 All payments shall be made hereunder in U.S. dollars; provided however, that if the proceeds
of the sales upon which such royalty payments are based are received by FIBROGEN in a foreign currency or other form that is not convertible or exportable in dollars, and FIBROGEN does not have ongoing business operations or bank accounts in the
country in which the currency is not convertible or exportable, FIBROGEN shall pay such royalties in the currency of the country in which such sales were made by depositing such royalties in LICENSOR’s name in a bank designated by the LICENSOR
in such country. Royalties in dollars shall be computed by converting the royalty in the currency of the country in which sales were made at the exchange rate for dollars prevailing at the close of the business day of FIBROGEN’s period for
which royalties are being calculated as published the following day in the Wall Street Journal (or, if it ceases to be published, a comparable publication to be agreed upon from time to time by the parties), and with respect to those countries for
which rates are not published in the Wall Street Journal, the exchange rate fixed for such date by the appropriate United States governmental agency. 

4.6 In the event the royalties set forth herein are higher than the maximum royalties permitted by law or regulation of a particular country,
the royalty payable for sales in such country shall be equal to the maximum permitted royalty under such law or regulation. 
 4.7 In the
event that any taxes, withholding or otherwise, are levied by any taxing authority in connection with accrual or payment of any royalties payable to LICENSOR under this Agreement, FIBROGEN shall have the right to pay such taxes to the local tax
authorities on behalf of the LICENSOR and the payment to LICENSOR of the net amount due after reduction by the amount of such taxes, shall fully satisfy FIBROGEN’s royalty obligations under this Agreement. 

ARTICLE 5 
 Reports And Records

 5.1 FIBROGEN shall keep full, true and accurate books of account containing all particulars that may be necessary for the purpose of
showing the amounts payable to LICENSOR by way of royalty as aforesaid. Said books of account shall be kept at FIBROGEN’s principal place of business or the principal place of business as of the appropriate division of FIBROGEN to which this
Agreement relates. Said books and the supporting data shall be open at all reasonable times, but not exceeding [ * ] per calendar year, for three (3) years following the end of the calendar year to which they pertain, to the
inspection of LICENSOR and/or an independent certified public accountant retained or employed by LICENSOR for the purpose of verifying FIBROGEN’s royalty or other payment statement. 

Such Accountant or Accounting Firm shall not disclose to LICENSOR any information other than that information relating solely to the accuracy
of, or necessity for, the reports and payments made hereunder. The fees and expense of the Certified Public Accountant or Accounting Firm performing such verification shall be borne by LICENSOR unless in the event that the audit reveals underpayment
of royalties by an amount more than ten (10) percent, the cost of such audit shall be paid by FIBROGEN. 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 5.2 FIBROGEN, within sixty (60) days after
March 31, June 30, September 30, and December 31 of each year, shall deliver to LICENSOR true and accurate reports, giving such particulars of the business conducted during the preceding three month period under this
Agreement as shall be pertinent to a royalty accounting hereunder. These shall include at least the following: 
 (a) all Licensed
Product(s) manufactured and sold; 
 (b) total billings for Licensed Product(s) sold; 

(c ) accounting for all the Licensed Process(es) used or sold; 

(d) deductions applicable as provided in the definition of Net Sales; 

(e) Net Royalties paid FIBROGEN, if relevant to the calculations of royalties to be paid to LICENSOR; 

(f) royalties due LICENSOR; and 

(g) names and addresses of all sublicensees. 

5.3 With each such report submitted, FIBROGEN shall pay to LICENSOR the royalties due and payable under this Agreement. It no royalties shall
be due, FIBROGEN shall so report. 
 5.4 The royalty payments sat forth in this Agreement shall, if overdue, bear interest until payment at
a [ * ] rate per annum. The payment of such interest shall not foreclose LICENSOR from exercising any other rights it may have as a consequence of the lateness of the payment. 

ARTICLE 6 
 Patent Prosecution

 6.1 FIBROGEN agrees to pay for the filing, prosecution and maintenance of all Patent Rights, and to diligently pursue same. If, in
any country agreed upon by FIBROGEN and LICENSOR for the filing of a Patent Rights Patent Application, FIBROGEN fails so to file, prosecute and maintain, LICENSOR may take over the responsibilities of filing, prosecution and maintenance, at the
expense of FIBROGEN, and will thereafter provide FIBROGEN with all relevant documentation. 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 6.2 FIBROGEN agrees promptly to furnish to LICENSOR copies of: 

(a) Patent Rights Patent Applications filed in any Patent Office; 

(b) papers received from a Patent Office pertaining to a Patent Rights Patent Application; and 

(c) papers filed in a Patent Office pertaining to a Patent Rights Patent Application. 

ARTICLE 7 
 Infringement

 Infringement By Third Parties 

7.1 The parties shall promptly inform each other in writing of any alleged infringement by a third party, of which it shall have notice, of any
patents within the Patent Rights, and provide the other party with any available evidence of infringement. 
 7.2 During the term of this
Agreement, FIBROGEN shall have the right, but shall not be obligated, to prosecute at its own expense any such infringements of the Patent Rights and, in furtherance of such right, LICENSOR hereby agrees to join FIBROGEN as a nominal party plaintiff
in any such suit where required for jurisdictional purposes, and to render to FIBROGEN every assistance within its power, except financial assistance. If LICENSOR should incur any out-of-pocket costs in connection with assisting FIBROGEN with said
suit, such costs shall be reimbursed to LICENSOR by FIBROGEN. The total cost of any such infringement action commenced or defended solely by FIBROGEN shall be borne by FIBROGEN, and FIBROGEN shall keep any net recovery or damages for patent
infringement derived therefrom, subject to reimbursement to LICENSOR for any royalties past due or withheld and applied pursuant to Section 7.3 below. 

7.3 In the event that FIBROGEN shall undertake the enforcement of the Patent Rights by litigation, FIBROGEN may withhold up to
[ * ] of the royalties otherwise thereafter due LICENSOR hereunder, and apply the same toward [ * ] of its expenses, including reasonable attorney’s fees, in connection therewith. 

7.4 If within [ * ] months after having been notified of any alleged infringement, FIBROGEN shall have been unsuccessful in
persuading the alleged infringer to desist, and shall not have brought or shall not be diligently prosecuting an infringement action, or if FIBROGEN shall notify LICENSOR at any time prior thereto of its intention not to bring suit against any
alleged infringer, then, and in these events only, LICENSOR shall have the right, but shall not be obligated, to prosecute at its own expense any infringement of the Patent Rights. No settlement, consent Judgment or other voluntary final disposition
of the suit may be entered into without the consent of FIBROGEN, which consent shall not be unreasonably withheld. The total cost of any such infringement action commenced solely by LICENSOR shall by borne by LICENSOR, and LICENSOR shall keep any
recovery or damages for past infringement derived therefrom. 
 7.5 In any infringement suit that either party may institute to enforce the
Patent Rights pursuant to this Agreement, the other party hereto shall, at the request and expense of the party initiating such suit, cooperate in all respects and, to the extent possible, have its employees testify when requested, and make
available relevant records, papers, information, samples, specimens, and the like. 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 Infringement By LICENSOR and FIBROGEN 

7.6 FIBROGEN shall promptly notify LICENSOR in writing of any claim of patent infringement which has been asserted against FIBROGEN or
LICENSOR, its Affiliate and any sublicensees because of the manufacture, use, promotion or sale of Licensed Products or Licensed Processes or the sale of products used according to the Licensed Methods. 

7.7 FIBROGEN shall have the first and primary right and responsibility to defend and control the defense of any such claim, by counsel of its
choice and at its expense. FIBROGEN will defend, indemnify and hold harmless LICENSOR, its Trustees, officers, directors, employees and its Affiliates against any and all judgment and damages arising from any and all third party claims of Patent
Rights infringement which may be asserted against LICENSOR, and its Affiliates because of the manufacture, use, promotion and sale of products. 

7.8 It is understood that any settlement of such action must be approved by LICENSOR, and that such approval shall not be unreasonably
withheld. LICENSOR agrees to cooperate with FIBROGEN in any reasonable manner necessary in defending such action. FIBROGEN shall reimburse LICENSOR for any reasonable out-of-pocket expenses incurred in providing such assistance. 

7.9 LICENSOR shall have no responsibility with respect to FIBROGEN’s own trademarks and tradename, and FIBROGEN in respect to the use
thereof will defend, indemnify and hold harmless LICENSOR against any and all third party claims. 
 7.10 In the event FIBROGEN deems it
necessary to seek a license from any third party in order to avoid infringement or settle an infringement action in any country of such third party’s patent rights brought about by the sale of Licensed Products or use of Licensed Processes,
[ * ] of all fees or royalties paid under such license may be deducted from royalty payments due LICENSOR on Sale of Licensed Products in such country to an extent not exceeding [ * ] of each such royalty payment as
it becomes due. 
 7.11 LICENSOR warrants and represents that it has the lawful right to grant the license provided in this Agreement and that, to its
knowledge and belief, it has not granted rights or licenses in derogation of the rights granted to FIBROGEN under this Agreement. LICENSOR agrees that during the term of this Agreement, it shall use reasonable efforts to avoid granting rights to
third parties or incurring obligations which will interfere with the rights and obligations of parties under this Agreement, including any rights and obligations that survive termination of this Agreement. 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 ARTICLE 8 

Product Liability, Indemnification and Warranties 

8.1 FIBROGEN agrees to release, indemnify and hold harmless the LICENSOR, its Trustees, officers, faculty, employees and students against any
and all losses, expenses, claims, actions, lawsuits and judgments thereon (including attorney’s fees through the appellate levels) which may be brought against LICENSOR, its Trustees, officers, faculty, employees or students as a result of or
arising out of use, production, manufacturer, sale, lease, consumption or advertisement by FIBROGEN or any third party of any Licensed patent, Product, Invention or Technology licensed under this Agreement. 

8.2 LICENSOR MAKES NO WARRANTIES, EXPRESS OR IMPLIED, AND HEREBY DISCLAIMS ALL SUCH WARRANTIES, AS TO ANY MATTER WHATSOEVER, INCLUDING,
WITHOUT LIMITATION, THE CONDITION OF ANY INVENTION(S) OR PRODUCT, WHETHER TANGIBLE OR INTANGIBLE, LICENSED UNDER THIS AGREEMENT; OR THE MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE OF THE INVENTION OR PRODUCT; OF THAT THE USE OF THE LICENSED
PRODUCT WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER RIGHTS, LICENSOR SHALL NOT BE LIABLE FOR ANY DIRECT, CONSEQUENTIAL, OR OTHER DAMAGES SUFFERED BY ANY LICENSEE OR ANY THIRD PARTY RESULTING FROM THE USE, PRODUCTION, MANUFACTURE,
SALE LEASE, CONSUMPTION, OR ADVERTISEMENT OF THE PRODUCT. 
 8.3 The provisions of 8.1 and 8.2 above shall continue beyond the termination
of this Agreement. 
 ARTICLE 9 

Assignment 
 9.1 Except as
otherwise provided in this Article, this Agreement is not assignable by FIBROGEN or by operation of law without the prior written consent of LICENSOR at its sole discretion. 

9.2 This Agreement shall extend to and be binding upon the successors and legal representatives and permitted assigns of LICENSOR and
FIBROGEN. 
 9.3 FIBROGEN may assign or otherwise transfer this Agreement and the license granted hereby and the rights acquired by it
hereunder, so long as such assignment or transfer shall be accompanied by a sale or other transfer of substantially all of FIBROGEN’s entire business, or that part of FIBROGEN’s business to which the license granted hereby relates. 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 9.4 FIBROGEN may assign or otherwise transfer this Agreement and the license granted hereby and
the rights acquired by it hereunder, so long as such assignment or transfer is made to a FIBROGEN subsidiary or Affiliate. 
 ARTICLE 10 

Use Of Names 
 FIBROGEN
shall not use the name of the University of Miami, or any of its employees, or any adaptation thereof, in any publication, including advertising, promotional or sales literature without the prior written consent of Mr. Alan J. Fish,
Assistant Vice President of Business Services, 327 Max Orovitz Building, 1507 Levante Avenue, Coral Gables, FL 33124-1432. Notwithstanding this provision, FIBROGEN may state that it has licensed one or more patents comprising the Patent Rights from
LICENSOR. 
 ARTICLE 11 

Export Controls 
 11.1 It
is understood that LICENSOR is subject to United States laws and regulations controlling the export of technical data, computer software, laboratory prototypes and other commodities (including the Arms Export Control Act, as amended, and the Export
Administration Act of 1979), and that its obligations hereunder are contingent upon compliance with applicable United States export laws and regulations. The transfer of certain technical data and commodities may require a license from the cognizant
agency of the United States Government and/or written assurances by LICENSOR that FIBROGEN shall not export data or commodities to certain foreign countries without prior approval of such agency. LICENSOR neither represents that a license shall not
be required, nor that, if required, it shall be issued. 
 ARTICLE 12 

Termination 
 12.1 LICENSOR
and FIBROGEN shall have the right to terminate this Agreement if the other party commits a material breach of an obligation under this Agreement or provides a false report and continues in default from more than [ * ] after
receiving written notice of such default or false report. Such termination shall be effective upon further written notice to the breaching party after failure by the breaching party to cure such default. If LICENSOR commits a material breach or
defaults, the FIBROGEN has no duty to continue the payment of royalties as set forth in Article IV of this Agreement. 
 12.2 The license
and rights granted in this Agreement have been granted on the basis of the special capability of FIBROGEN to perform research and development work leading to the manufacture and marketing of the Products. Accordingly, FIBROGEN covenants and agrees

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 
that in the event any proceedings under the Bankruptcy Act of any amendment thereto, be commenced by or against FIBROGEN, and, if against FIBROGEN, said proceedings shall not be dismissed with
prejudice before either an adjudication in bankruptcy or the confirmation of a composition, arrangement, or plan of reorganization, or in the event FIBROGEN shall be adjudged insolvent or make an assignment for the benefit of its creditors, or if a
writ of attachment or execution be levied upon the license hereby created and not be released or satisfied within [ * ] days after thereafter, or if a receiver be appointed in any proceedings or action to which FIBROGEN is a party
with authority to exercise any of the rights or privileges granted hereunder and such receiver be so discharged within a period of [ * ] days after his appointment, any such event shall be deemed to constitute a breach of this
Agreement by FIBROGEN and, LICENSOR, at the election of LICENSOR, but not otherwise, ipso facto, and without notice or other action by LICENSOR, shall terminate this Agreement and all rights of LICENSOR hereunder and all rights of any and all
persons claiming under FIBROGEN. 
 12.3 FIBROGEN shall have the right to terminate this Agreement upon ninety (90) days notice. 

12.4 Any termination of this Agreement shall be without prejudice to LICENSOR’s right to recover all amounts accruing to LICENSOR prior
to such termination and cancellation. Except as otherwise provided, should this Agreement be terminated for any reason, FIBROGEN shall have no rights, express or implied, under any patent property which is the subject matter of this Agreement, nor
have the right to recover any royalties paid LICENSOR hereunder. Upon termination of this Agreement for any reason, nothing herein shall be construed to release either party from any obligation that matured prior to the effective date of such
termination. FIBROGEN and/or any sublicensee of FIBROGEN may, however, after the effective date of such termination, sell all Licensed Product(s), and complete Licensed Product(s) in the process of manufacture at the time of such termination and
sell the same, provided that FIBROGEN shall pay to LICENSOR the royalties thereon as required by Article 4 of this Agreement, and shall submit the report required by Article 5 hereof on the sales of Licensed Product(s). 

ARTICLE 13 
 Payments, Notices
And Other Communications 
 Any notice, payment, report or other communication (hereinafter collectively referred to as
“correspondence”) required to be given hereunder shall be mailed by certified mail or delivered by hand to the party to whom such correspondence is required or permitted to be given hereunder. If mailed, any such notice shall be deemed to
have been given when mailed as evidenced by the postmark at point of mailing. If delivered by hand, any such correspondence shall be deemed to have given when received by the party to whom such correspondence is given, as evidenced by written and
dated receipt of the receiving party. 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 All correspondence to FIBROGEN shall be addressed as follows: 

FibroGen, Inc. 
 260 Littlefield
Avenue 
 South San Francisco, CA 94080 

Attention: President 
 All correspondence to
LICENSOR shall be addressed, in duplicate, as follows: 
 FOR NOTICE BY MAIL: 

University of Miami 
 School of
Medicine 
 Research and Graduate Studies 

P.O. Box 016960 (R64) 
 Miami, FL
33101 
 Attention: Dr. Norman H. Altman 

Assistant Vice President for Business Affairs 

327 Max Ororvitz Building 
 1507
Levante Avenue 
 Coral Gables, FL 33124-1432 

Attention: Mr. Alan J. Fish 

FOR NOTICE AND PAYMENT: 
 BY MAIL:

 Director 
 Office of
Technology Transfer 
 P.O. Box 016960 ((M811) 

Miami, FL 33101 
 Attention:
Dr. Gary S. Margules 
 BY HAND: 

Director 
 Office of Technology
Transfer 
 P.O. Box 016960 (M811) 

Miami, FL 33101 
 Attention:
Dr. Gary S. Margules 
 Either party may change the address to which correspondence to it is to be addressed by notification as provided herein.

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 ARTICLE 14 

Governing Law 
 This
Agreement shall be construed, governed, interpreted and applied in accordance with the laws of the State of Florida, except that questions affecting the construction and effect of any patent shall be determined by the law of the country in which
such patent was granted. 
 ARTICLE 15 

Captions 
 The captions and
paragraph headings of this Agreement are solely for the convenience of reference and shall not affect its interpretation. 
 ARTICLE 16 

Entire Agreement 
 This
Agreement constitutes the entire Agreement between the parties hereto respecting the subject matter hereof, and supersedes and terminates all prior agreements respecting the subject matter hereof, whether written or oral, and may be amended only by
an instrument in writing executed by both parties hereto. 
 ARTICLE 17 

Amendment 
 No amendment or
modification of the terms of this Agreement shall be binding on either party unless reduced to writing and signed by an authorized officer of the party to be bound. 

ARTICLE 18 
 Severability

 Should any part or provision of this Agreement be held unenforceable or in conflict with the applicable laws or regulations of any
jurisdiction, the invalid or unenforceable part of provision shall be replaced with a provision which accomplishes, to the extent possible, the original business purposes of such part or provision in valid and enforceable manner, and the remainder
of the Agreement shall remain binding upon the parties hereto. 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 ARTICLE 19 

Waiver 
 No failure or
delay on the part of a party in exercising any right hereunder will operate as a waiver of, or impair, any such right. No single or partial exercise of any such right will preclude any other or further exercise thereof or the exercise of any other
right. No waiver of any such right will be deemed a waiver of any other right hereunder. 
 ARTICLE 20 

Marking 
 Prior to the
issuance of patents on the Invention(s), FIBROGEN agrees to mark and have sublicensees mark Licensed Products (or their containers or labels) made, sold, or otherwise disposed of by it under the license granted in this Agreement with a proper notice
as specified under the patents laws of the United States. All Licensed Product(s) shipped to or sold in other countries shall be marked in such a manner as to conform with the patent law and practice of the country of manufacture or sale. 

ARTICLE 21 
 Standards 

FIBROGEN further agrees to maintain satisfactory standards in respect to the nature of the Product manufactured and/or sold by FIBROGEN.
FIBROGEN, agrees that all Licensed Product(s) manufactured and/or sold by it shall be of a quality which is appropriate to products of the type here involved. FIBROGEN agrees that similar provisions shall be included by sublicensees of all tiers.

 ARTICLE 22 
 United States
Law, Public Law 96-517 as Amended 
 This Agreement is subject to all of the terms and conditions of Public Law 96-517 as amended, and
FIBROGEN agrees to take all action necessary on its part as LICENSEE to enable LICENSOR to satisfy its obligation thereunder, relating to Invention(s). 

ARTICLE 23 
 Certificate of
Insurance 
 23.1 FIBROGEN shall maintain liability insurance coverage for the Licensed Product in the amount of five million dollars
($5,000,000.00) and at no expense to LICENSOR, FIBROGEN shall name LICENSOR as an additional insured. Prior to the first human use of the Licensed Product, FIBROGEN shall provide a certificate of insurance to LICENSOR. 

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

 23.2 FIBROGEN agrees to carry and keep in force, at its expense, general liability insurance with
limits not less than one million ($1,000,000.00) per person and three million ($3,000,000.00) aggregate to cover liability for damages on account of bodily injury or personal injury or death to any person, or damage to property of any person; such
insurance shall not be canceled for any cause without at least thirty (30) days prior written notice to University of Miami. Such insurance shall contain an endorsement naming the University as an additional insured with respect to this
Agreement. Insurance Certificates should be sent to the University of Miami, attention Mr. William Coombs, 333 Max Orovitz Building, 1507 Leavante Avenue, Coral Gables, FL 33124-1437. 

ARTICLE 24 
 Survival 

24.1 The provisions of Article7, and Article 8 shall survive the termination or expiration of this Agreement and shall remain in full force
and effect. 
 24.2 The provisions of the Agreement which do not survive termination or expiration hereof (as the case may be) shall,
nonetheless, be controlling on, and shall be used in construing and interpreting, the rights and obligations of the parties hereto with regard to any dispute, controversy or claim which may arise under, our of, in connection with, or relating to
this Agreement. 
 IN WITNESS WHEREOF, the parties hereto have hereunto set their hands and seals and duly executed this License Agreement on the day and
year first set forth below. 
  

									
	Dated: May 23, 1997	 		 	UNIVERSITY FOR MIAMI
				
		 		 	By:	 	 /s/ Alan J. Fish

		 		 		 	[name]	 	Alan J. Fish
		 		 		 	[title]	 	Assistant Vice Pres. Business Services

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended. 

							
	Dated: May 2, 1997	 		 	FIBROGEN, INC.
				
		 		 	By:	 	 /s/ Thomas B. Neff

		 		 		 	Thomas B. Neff
		 		 		 	Chief Executive Officer

  
 [ * ] = Certain
confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00236-of-00352.parquet"}]]